PLUS1
Best deals to access real time data! |
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Big Cap Pro
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Denali Therapeutics Inc | DNLI | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 1.74 | 7.0% | 26.58 | 26.94 | 24.67 | 24.80 | 24.84 | 10:31:44 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 26.54 | 26.59 | 0.05 | 0.19% | - | 1 |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 9,921 | 1,641,074 | $ 25.35 | $ 41,601,510 | 522,242 | 14.24 - 30.41 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:31:43 | 100 | $ 26.58 | USD |
Denali Therapeutics Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 2.55B | 96.03M | $ -36.24M | -0.38 | - | 91.56M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Denali Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 1/28/2020 | 20:58 | GlobeNewswire Inc. | Denali Therapeutics Announces Pricing of Public Offering of.. |
| 1/27/2020 | 17:14 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/27/2020 | 17:13 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) |
| 1/27/2020 | 16:10 | GlobeNewswire Inc. | Denali Therapeutics Announces Proposed Offering of Common.. |
| 1/16/2020 | 10:42 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) |
| 1/14/2020 | 09:00 | GlobeNewswire Inc. | Denali Therapeutics Announces Broad Pipeline Progress.. |
| 12/19/2019 | 08:00 | PR Newswire (US) | Flagship Unveils Newest Pioneering Platform: Ring.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DNLI Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 22.18 | 30.41 | 21.81 | 25.89 | 1,416,265 | 4.40 | 19.84% |
| 1 Month | 17.56 | 30.41 | 16.02 | 22.99 | 842,985 | 9.02 | 51.37% |
| 3 Months | 16.57 | 30.41 | 14.5142 | 20.62 | 485,280 | 10.01 | 60.41% |
| 6 Months | 21.37 | 30.41 | 14.24 | 19.12 | 383,946 | 5.21 | 24.38% |
| 1 Year | 20.53 | 30.41 | 14.24 | 20.46 | 376,181 | 6.05 | 29.47% |
| 3 Years | 21.55 | 30.41 | 12.32 | 19.51 | 386,320 | 5.03 | 23.34% |
| 5 Years | 21.55 | 30.41 | 12.32 | 19.51 | 386,320 | 5.03 | 23.34% |
Denali Therapeutics Description
| Denali Therapeutics Inc is a biotechnology company which is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include LRRK2 Inhibitor Program which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle) and others. |
